Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target

Abstract excerpt

Inhibitors of various elements of the DNA repair pathways have entered clinical development or are in late preclinical stages of drug development. It was initially considered that agents targeting DNA repair would act to overcome tumor resistance to chemotherapy and radiotherapy. More recent data have shown that targeting DNA repair pathways can be effective in selected tumors via a synthetically lethal route,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer therapeutics and mechanisms
• Share to DNA Repair Mechanisms
• Share to PARP inhibition in cancer therapy